Alternatives to DrBrainRx

FDA warning letter #728291 (Jun. 2026), which names orderlymeds.com. One of the few sites in this round to publish real cash prices for both compounded ($149/mo semaglutide, $299/mo tirzepatide) and FDA-approved brand-name options (Wegovy® $1,839/mo, Zepbound® $1,498/mo) — a named Chief Medical Officer, and licensed in all 50 states. It also cites customer-reported outcomes (125k patients, 1M+ pounds lost) rather than leaving weight-loss claims unsourced.

LegitScript-certified and available in all 50 states at $149/mo ongoing (after a $124 first month) for compounded semaglutide — but it's a broad IV-therapy-and-hormone platform first, its own homepage banner prices the same program differently than its product page, and tirzepatide isn't offered as a compounded option. It also runs mobile IV therapy (Texas only), hormone replacement, and hair regrowth under the same brand, dispensing through 503A and 503B U.S.-licensed pharmacies per its own claim.

The number on the page is a prepay. Read live on 2026-08-26, GOAL.MD's semaglutide page leads with $99 a month and its tirzepatide page with $159 — and both are 12-month prepaid equivalents, $1,188 and $1,908 handed over up front. Month to month, the same two medications are $179 and $249. The site does say so, in the same sentence, but second. Everything around that pricing is unusually clean for this roster: a named physician with a searchable NPI rather than an anonymous clinical network, "No Auto-Billing. Ever." with a stated check-in before every renewal, a 3-minute online medical visit with no video call mentioned anywhere in the copy, and a published timeline — physician decision in about 24 hours, free shipping in 2–3 days. Two corrections to make if you are comparing: it serves 48 states rather than the whole country, and its brand-name lane is a forwarding service where you pay GOAL.MD $95 a month for supervision and the manufacturer program directly for the drug.

A broader wellness platform (GLP-1s plus NAD+, sermorelin, HRT, hair growth) offering both compounded ($199/mo semaglutide, $299/mo tirzepatide) and brand-name Ozempic/Zepbound access — though the site shows three different, unreconciled price claims across its own pages, so confirm the real number at signup. The three are the $199/mo standing tier, a $169/mo three-month prepay plan badged 'Best Value', and a countdown-timer banner advertising 'as low as $119/mo' that matches neither. Brand-name access is listed only as 'also available', with no price shown on any page we checked, so the compounded tiers are the only figures you can plan around.

A straightforward compounded-only shop with real prices for every tier on the public site — no intake gate — but the 'Starter Pack' name is a trap if you assume it behaves like the regular 3-month plan.

A same-day-provider-access platform offering compounded tirzepatide from $189/mo alongside brand-name Ozempic/Zepbound/Mounjaro access — but no compounded semaglutide option, so semaglutide-specific readers pay brand-name prices starting at $345/mo.

A named-Medical-Director program licensed in all 50 states, from $99/mo semaglutide and $183/mo tirzepatide, with no membership required — but it carries a 2025 FDA warning letter over how it described its compounded medication, and both prices are 'From' starting prices rather than a guaranteed working-dose rate.

This record changed completely between checks, and mostly for the better. The founding-member framing that dominated it a week ago is gone: read live on 2026-08-26 KERNX simply says "Semaglutide starts at $129/month and Tirzepatide starts at $229/month. Pricing varies by prescribed dose. No membership fee. No required 3 month plan." What has not gone is the cost outside those figures, and KERNX is unusually straight about it — a provider consultation fee applies when treatment is approved, at $25 for a message-based review, $35 for a standard live visit or $60 for a complex live visit. Two more things this record previously had wrong. It does say where it operates: licensed providers in all 50 states, repeated in its banner and its FAQ. And it publishes a real timeline: a free five-minute assessment, provider review typically within 24 hours, pharmacy processing 1–2 business days and transit 2–3, so most first orders arrive within three to five business days of approval. It also says nothing is charged until a provider approves you.

Flat compounded pricing with the post-introductory number actually printed: $149 a month for semaglutide and $229 for tirzepatide, the same at every dose, after intro rates of $119 and $199. For planning purposes that flatness is the useful part — a titration step-up does not change the bill, so the number you budget in month one is the number in month six. All 50 states, and consultation, prescription, medication, shipping and support are inside the price. Watch the word "from" on every figure: the site says dosage and titration can move what you pay.